

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CHINA BIOTECH SERVICES HOLDINGS LIMITED**

**中國生物科技服務控股有限公司**

*(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)*

**(Stock code: 8037)**

### **VOLUNTARY ANNOUNCEMENT MEMORANDUM OF UNDERSTANDING WITH THE CHINESE UNIVERSITY OF HONG KONG**

This announcement is made by China Biotech Services Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to keep shareholders of the Company (the “**Shareholders**”) and potential investors informed of the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on 2 May 2023 (after trading hours), the Company and The Chinese University of Hong Kong (“**CUHK**”, together with the Company, the “**Parties**”), entered into a memorandum of understanding (the “**MOU**”), pursuant to which the Parties have agreed, among other things, to collaborate towards the development of the Greater Bay Area Diagnosis and Treatment Integrated Research and Development Transformation and Application Center (the “**GBA Cancer DTIRA Centre**”) in the Shenzhen-Hong Kong Innovation and Technology Cooperation Zone situated in the Lok Ma Chau Loop.

## THE MOU

The principal terms of the MOU are set out below:

Date: 2 May 2023

Parties: (i) The Company; and  
(ii) CUHK.

Subject matter: Pursuant to the MOU, the Parties agreed to cooperate in the following matters:

- (1) The Parties will jointly engage in the research and development of technologies, translating research results into practical applications, and contributing to local and national social-economic and technological development strategies;
- (2) The Parties will carry out close cooperation in developing novel treatment for both solid and liquid tumors, such as using boron neutron capture therapy (“**BNCT**”) and cell therapy;
- (3) The Parties will work closely to form a synergistic collaboration on the development of the Shenzhen-Hong Kong Science and Technology Innovation Cooperation Zone;
- (4) The Parties will collaborate on advancing biomedical research, delivering high-quality clinical services (BNCT and cell therapy), and strengthening university-government-industry partnerships in nurturing technology transformation in Shenzhen Longgang ENT Hospital; and
- (5) The Parties will engage in translation research collaboration, talent development as well as clinical development and adoption at the Institute of Innovative Biomedicine in Hong Kong to be established by CUHK.

Term: Two (2) years from the date on which the MOU is signed (the “**Term**”). The Parties may extend the Term by mutual written agreement to be entered into thirty (30) days before the expiry of the Term.

## **REASONS FOR AND BENEFITS OF ENTERING INTO THE MOU**

Founded in 1963, CUHK is a forward-looking comprehensive research university with a global vision and a mission to combine tradition with modernity, and to bring together China and the West. The Board believes that the entering into of the MOU with CUHK will be beneficial to the development of the Group's immuno cell therapy and BNCT segments and will help the Company build an integrated cancer treatment centre in the Greater Bay Area, thereby enhancing the Company's position and market share in the biotechnology industry in Hong Kong and the Greater Bay Area.

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**China Biotech Services Holdings Limited**  
**Liu Xiaolin**  
*Chairman and Executive Director*

Hong Kong, 2 May 2023

*As at the date of this announcement, the Board comprises four executive Directors, namely, Mr. Liu Xiaolin (Chairman), Mr. He Xun, Mr. Huang Song and Ms. Chui Hoi Yam; and three independent non-executive Directors, namely, Mr. Yan Guoxiang, Dr. Ho Ivan Chun Kit and Mr. Qian Hongji.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on GEM of The Stock Exchange of the Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief, the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the "Latest Listed Company Information" page of the website of The Stock Exchange of Hong Kong Limited at [www.hkexnews.hk](http://www.hkexnews.hk) for at least 7 days from the date of its publication and on the website of the Company at [www.cbshhk.com](http://www.cbshhk.com).*